Gary Dahl

Professor of Pediatrics (Hematology/Oncology)

Clinical Focus

Pediatric Hematology-Oncology
Ped Hematology/Oncology

Academic Appointments

Professor - University Medical Line, Pediatrics - Hematology & Oncology
Member, Maternal & Child Health Research Institute (MCHRI)
Member, Stanford Cancer Institute

Professional Education

Residency: Oregon Health and Science University Pediatric Residency (1974) OR
Internship: Oregon Health Sciences University Internal Medicine Residency (1968) OR
Board Certification: American Board of Pediatrics, Pediatrics (1976)
Fellowship: St Jude Children's Research Hospital (1976) TN
Board Certification: American Board of Pediatrics, Pediatric Hematology-Oncology (1976)
Medical Education: University of Oregon Medical School (1967) OR

Contact

Academic gary.dahl@stanford.edu Tel: (650) 723-5114Tel: (650) 723-5535 Fax: (650) 723-5231

Clinical Pediatric Hematology and Oncology 725 Welch Rd MC 5798 Palo Alto CA 94304 Tel: (650) 497-8953 Fax: (650) 497-8959

Current Research and Scholarly Interests

Hematology/Oncology, Phase I drug studies for childhood cancer, overcoming multidrug resistance in leukemia and solid tumors, biology and treatment of acute nonlymphocytic leukemia, early detection of central nervous system leukemia by measuring growth, factor binding proteins.

Clinical Trials

Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well neoadjuvant chemotherapy works in treating young patients who are undergoing surgical resection for high-risk hepatoblastoma.

Stanford is currently not accepting patients for this trial. For more information, please contact Nadeem Mukhtar, 6507251662.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes Not Recruiting
More
This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with relapsed or refractory solid tumors or myelodysplastic syndromes. Lenalidomide may stop the growth of solid tumors or myelodysplastic syndromes by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing.

Stanford is currently not accepting patients for this trial. For more information, please contact LPCH New Patient Coordinator, 6507251072.
Lead Sponsor
Stanford Investigators
- Neyssa Marina
- Gary Dahl
View full details
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma Not Recruiting
More
This dose-escalating study is to determine the safety, pharmacokinetics, and preliminary efficacy of venetoclax in combination with navitoclax and chemotherapy in adult and pediatric participants with relapsed/refractory acute lymphoblastic leukemia (ALL) or relapsed/refractory lymphoblastic lymphoma. A safety expansion cohort of approximately 20 patients may be enrolled in addition to the 50 participants in dose-escalation cohort.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia Not Recruiting
More
This phase I trial is studying the side effects and best dose of vorinostat when given together with isotretinoin in treating young patients with recurrent or refractory solid tumors, lymphoma, or leukemia. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Isotretinoin may cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving vorinostat together with isotretinoin may be an effective treatment for cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Min Wang, 6507364281.
Lead Sponsor
Stanford Investigators
- Neyssa Marina
- Gary Dahl
View full details
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Recruiting
More
This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. These proteins are commonly found on B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CD19/CD22-CAR T cells and chemotherapy may work better in treating children or young adults with B acute lymphoblastic leukemia.
Lead Sponsor
Stanford Investigators
View full details
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. Not Recruiting
More
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted. The purpose of the phase 1 portion of this study was to determine if clofarabine added to a combination of etoposide and cyclophosphamide is safe in children with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). The purpose of the phase 2 portion of the study was to measure the effectiveness of the combination therapy in children with ALL.

Stanford is currently not accepting patients for this trial. For more information, please contact Min Wang, 6507364281.
Lead Sponsor
Stanford Investigators
- Neyssa Marina
- Gary Dahl
View full details
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Valproic acid may also stop the growth of solid tumors or CNS tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of valproic acid in treating patients with recurrent or refractory solid tumors or CNS tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact LPCH New Patient Coordinator, 6507251072.
Lead Sponsor
Stanford Investigators
- Neyssa Marina
- Gary Dahl
View full details
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia Not Recruiting
More
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.

Stanford is currently not accepting patients for this trial. For more information, please contact LPCH New Patient Coordinator, 6507251072.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with temozolomide and vincristine in treating young patients with refractory solid tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Nadeem Mukhtar, 6504978815.
Lead Sponsor
Stanford Investigators
- Neyssa Marina
- Gary Dahl
View full details
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Not Recruiting
More
The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy-haploidentical NK cell transplantation-in patients with standard-risk AML. In addition, we will investigate the efficacy of clofarabine + cytarabine (Clo/AraC) in newly diagnosed patients with AML and attempt to optimize outcome through the use of MRD-adapted therapy and further improvements in supportive care.

Stanford is currently not accepting patients for this trial. For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia Not Recruiting
More
BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating patients who have recurrent or refractory advanced T-cell leukemia. Patients will receive an infusion of BCX-1777 on days 1-5. Treatment may be repeated every week for up to six courses. Patients are not required to be hospitalized for the administration of BCX-1777. Some patients may continue to receive an infusion of BCX-1777 twice a week for 6 weeks.

Stanford is currently not accepting patients for this trial. For more information, please contact Nadeem Mukhtar, 6504978815.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia Not Recruiting
More
Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining PSC-833 with chemotherapy may reduce resistance to the drug and allow more cancer cells to be killed.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients Not Recruiting
More
This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.

Stanford is currently not accepting patients for this trial. For more information, please contact LPCH New Patient Coordinator, 6507251072.
Lead Sponsor
Stanford Investigators
- Gary Dahl
View full details
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate Not Recruiting
More
This phase I trial is studying the side effects and best dose of dasatinib in treating young patients with recurrent or refractory solid tumors or Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myelogenous leukemia that did not respond to imatinib mesylate. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

Stanford is currently not accepting patients for this trial. For more information, please contact Neyssa Marina, 6507235535.
Lead Sponsor
Stanford Investigators
- Neyssa Marina
- Gary Dahl
View full details
T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis Not Recruiting
More
To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).

Stanford is currently not accepting patients for this trial. For more information, please contact Nadeem Mukhtar, 6504978815.

Lead Sponsor
- Stanford University
Stanford Investigators
- Gary Dahl
View full details
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Not Recruiting
More
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating young patients with recurrent or refractory neuroblastoma.

Stanford is currently not accepting patients for this trial. For more information, please contact LPCH New Patient Coordinator, 6507251072.
Lead Sponsor
Stanford Investigators
- Neyssa Marina
- Gary Dahl
View full details
Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia Not Recruiting
More
We will study gene and protein expression in leukemia cells of children diagnosed with acute leukemia. We hope to identify genes or proteins which can help us grade leukemia at diagnosis in order to: (a) develop better means of diagnosis and (b) more accurately choose the best therapy for each patient.

Stanford is currently not accepting patients for this trial. For more information, please contact Norman J Lacayo, 650-723-5535.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details

2021-22 Courses

Independent Studies
- Directed Reading in Pediatrics
  PEDS 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience
  PEDS 280 (Aut, Win, Spr, Sum)
- Graduate Research
  PEDS 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  PEDS 370 (Aut, Win, Spr, Sum)
- Undergraduate Directed Reading/Research
  PEDS 199 (Aut, Win, Spr, Sum)

Graduate and Fellowship Programs

Pediatric Hem/Onc (Fellowship Program)

Find a doctor

Clinics & Services

Research Resources

Professional Training

Education Resources

Gary Dahl

Professor of Pediatrics (Hematology/Oncology)

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

2021-22 Courses

Graduate and Fellowship Programs